Conference Proceedings

Phase 3 zanubrutinib (BGB-3111) vs bendamustine plus rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Peter Hillmen, Jennifer R Brown, Brad S Kahl, Paolo Ghia, Tadeusz Robak, Carol Marimpietri, Aileen Cohen, Jane Huang, Constantine Si Lun Tam

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2018

DOI: 10.1200/JCO.2018.36.15_suppl.TPS7581

University of Melbourne Researchers

Citation metrics

3Web of Science
6Dimensions

Keywords

Life Sciences & Biomedicine
3201 Cardiovascular Medicine and Haematology
Lymphoma
Oncology
Rare Diseases
Cancer
Hematology
3211 Oncology and Carcinogenesis
Clinical Research
32 Biomedical and Clinical Sciences
Science & Technology
Lymphatic Research
Orphan Drug